% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Tichanek:277750,
      author       = {F. Tichanek and A. Försti$^*$ and O. Hemminki and A.
                      Hemminki and K. Hemminki$^*$},
      title        = {{S}urvival, {I}ncidence, and {M}ortality {T}rends in
                      {F}emale {C}ancers in the {N}ordic {C}ountries.},
      journal      = {Obstetrics and gynecology international},
      volume       = {2023},
      issn         = {1687-9589},
      address      = {New York, NY},
      publisher    = {Hindawi},
      reportid     = {DKFZ-2023-01467},
      pages        = {1 - 9},
      year         = {2023},
      note         = {#LA:C020# / 2023 Jul 7;2023:6909414},
      abstract     = {Female cancers cover common breast cancers, relatively
                      common endometrial, ovarian, and cervical cancers and rare
                      vulvar cancer. Survival in these cancers is known to be
                      relatively good compared to all cancers but long-term
                      studies for these cancers are rare, and to fill the gap,
                      here, we generate survival data through 50 years.We applied
                      generalized additive models to data from the NORDCAN
                      database and analyzed 1- and 5-year relative survival for
                      these cancers in Denmark (DK), Finland (FI), Norway (NO),
                      and Sweden (SE) over half a century (1971-2020). Conditional
                      5/1-year survival for patients who survived the 1st year
                      after diagnosis and annual survival changes was also
                      estimated.In 2016-20, 5-year survival was best for breast
                      cancer reaching $92.3\%$ (in SE), followed by endometrial
                      cancer at $86.1\%$ (SE) and cervical cancer at $75.6\%$
                      (NO). Improvement in 5-year survival over the 50 years was
                      the largest for ovarian cancer $(20\%$ units), finally
                      reaching $52.9\%$ (SE). For vulvar cancer, the final
                      survival was between 70 and $73\%.$ The best 5-year survival
                      rate in 2016-20 was recorded for SE in breast, endometrial,
                      and ovarian cancers; NO showed the highest rate for cervical
                      and DK for vulvar cancers. DK had the lowest survival for
                      breast and ovarian cancers, and FI, for the other
                      cancers.The overall survival development appeared to consist
                      of continuous improvements, most likely because of novel
                      treatment and imaging techniques as well as overall
                      organization of patient care. The large survival improvement
                      for ovarian cancer was probably achieved by a surgical focus
                      on tumors spread in the peritoneal cavity. For cervical and
                      vulvar cancers, the high early mortality requires attention
                      and could be helped by raising increasing public awareness
                      of early symptoms in these cancers and developing pathways
                      for fast initiation of treatment.},
      cin          = {B062 / HD01 / C020},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331 /
                      I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37457920},
      pmc          = {pmc:PMC10348860},
      doi          = {10.1155/2023/6909414},
      url          = {https://inrepo02.dkfz.de/record/277750},
}